BCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOCRYST PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$8.07+0.28 (+3.59%)
Close on Oct 19, 2026
- Market cap
- $2.14B
- P/E (TTM)
- –
- Dividend yield
- –
Biocryst Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $2.06B | $166.30M |
| Enterprise Value | $2.11B | $87.12M |
| PS Ratio | 2.19 | 3.60 |
| P/FCF Ratio | 5.52 | 17.44 |
| P/OCF Ratio | 5.48 | 13.32 |
Enterprise value
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 2.24 | 2.43 |
| EV / FCF | 5.64 | 20.97 |
Income (trailing twelve months)
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $940.61M | $57.94M |
| Gross Profit | $919.69M | $90.47M |
| Operating Income | -$313.16M | -$21.49M |
| Pretax Income | -$381.19M | -$14.72M |
| Net Income | -$384.67M | -$22.46M |
| EBITDA | -$313.16M | -$17.14M |
| EPS (Diluted) | -$1.50 | -$0.83 |
Margins
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 97.8% | 52.3% |
| Operating Margin | -33.3% | -44.5% |
| Pretax Margin | -40.5% | -13.0% |
| Profit Margin | -40.9% | -39.2% |
| EBITDA Margin | -33.3% | -31.3% |
| FCF Margin | 39.7% | -8.85% |
Returns
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Return on Assets (ROA) | -75.8% | -41.0% |
| Return on Capital Employed (ROCE) | -89.7% | -38.0% |
Growth
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 68.7% | 6.01% |
| FCF Growth (YoY) | 2269.0% | 2.34% |
| Revenue Growth (3Y CAGR) | 47.8% | 2.25% |
| Revenue Growth (5Y CAGR) | 117.9% | 6.42% |
Balance sheet
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $352.57M | $62.64M |
| Total Debt | $395.40M | $120.13M |
| Net Cash (Debt) | -$42.83M | $15.77M |
| Net Cash Per Share | -$0.17 | $0.66 |
| Equity (Book Value) | -$454.29M | $48.61M |
| Book Value Per Share | -$1.78 | $1.36 |
| Tangible Book Value | -$454.29M | $23.01M |
| Working Capital | $275.84M | $75.09M |
Financial position
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 2.32 | 3.30 |
| Quick Ratio | 2.22 | 2.39 |
| Debt / FCF | 1.06 | 5.05 |
| Interest Coverage | -4.16 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $376.14M | -$12.39M |
| Capital Expenditures | -$2.76M | -$1.07M |
| Free Cash Flow | $373.38M | -$20.34M |
| FCF Per Share | $1.46 | -$0.42 |
Efficiency
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 1.85 | 0.38 |
| Inventory Turnover | 3.77 | 2.67 |
| Revenue Per Employee | $2.16M | $398.96K |
| Profits Per Employee | -$884.31K | -$705.27K |
| Employee Count | 435 | 74 |
Dividends and yields
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | -18.7% | -22.8% |
| FCF Yield | 18.1% | -9.02% |
Shares
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 255,535,000 | 58,139,000 |
| Shares Change (YoY) | 11.4% | 11.1% |
| Shares Change (QoQ) | 0.49% | 0.54% |
| Float | 250,643,000 | 49,154,900 |
| Shares Held by Insiders | 1.91% | 11.6% |
| Shares Held by Institutions | 103.3% | 59.4% |
Taxes
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $3.49M | $89.00K |
Scores
| Measure | Biocryst Pharmaceuticals | Industry median |
|---|---|---|
| Altman Z-Score | -3.75 | -0.27 |
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -2.19 | -2.62 |
Calculated by StockData from Biocryst Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.